

Application for Quotation of Additional Securities

File Reference:

I:\Issuers\Frms\website forms\documents 2016\issuers\NSX Quotation of Additional Securities.doc

Table of Contents

INTRODUCTION.....	2
NEW ISSUE ANNOUNCEMENT, APPLICATION FOR QUOTATION OF ADDITIONAL SECURITIES AND AGREEMENT.....	3
PART 1 - ALL ISSUES.....	3
PART 2 - BONUS ISSUE OR PRO RATA ISSUE.....	5
PART 3 - QUOTATION OF SECURITIES.....	7
ADDITIONAL SECURITIES FORMING A NEW CLASS OF SECURITIES.....	7
QUOTATION AGREEMENT.....	9

Introduction

To ensure the efficient processing of this form by NSX, please:

1. Adhere to the suggested number of the annexures required by this form.
2. Complete **all** statements and questions in this form. (NSX can provide an electronic version of this form on request).



New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to NSX as soon as available. Information and documents given to NSX become NSX's property and may be made public.

Introduced 11 March 2004. Revised 7 March 2016.

Name of entity

SENERPRISYS LIMITED

ABN/ACN

14 146 845 123

We (the entity) give NSX the following information.

Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

- | | | |
|---|---|--|
| 1 | Class of securities issued or to be issued | ORDINARY |
| 2 | Number of securities issued or to be issued (if known) or maximum number which may be issued | NUMBER OF SECURITIES TO BE ISSUED IS 587,500 VIA AN EMPLOYEE SHARE SCHEME |
| 3 | Principal terms of the securities (eg, if options, exercise price and expiry date; if partly paid securities, the amount outstanding and due dates for payment; if convertible securities, the conversion price and dates for conversion) | FULLY PAID ORDINARY SHARES UNDER THE EMPLOYEE SHARE SCHEME AND RANKING EQUALLY WITH ALL OTHER FULLY PAID ORDINARY SHARES |
| 4 | <p>Do the securities rank equally in all respects from the date of allotment with an existing class of quoted securities?</p> <p>If the additional securities do not rank equally, please state:</p> <ul style="list-style-type: none">• the date from which they do• the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment• the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment | YES |




5	Issue price or consideration	\$0.10	
6	Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)	ISSUED UNDER AN EMPLOYEE SHARE SCHEME	
7	Dates of entering securities into uncertificated holdings or despatch of certificates	13 MARCH 2019	
8	Number and class of all securities quoted on NSX (including the securities in clause 2 if applicable)	Number 71,004,912	Class ORDINARY
9	Number and class of all securities not quoted on NSX (including the securities in clause 2 if applicable)	Number NIL	Class NIL
10	Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)	N/A	

11	Is security holder approval required?	NO
12	Is the issue renounceable or non-renounceable?	NON-RENOUNCEABLE
13	Ratio in which the securities will be offered	N/A
14	Class of securities to which the offer relates	ORDINARY
15	Record date to determine entitlements	N/A
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	NO
17	Policy for deciding entitlements in relation to fractions	NIL
18	Names of countries in which the entity has security holders who will not be sent new issue documents Note: Security holders must be told how their entitlements are to be dealt with.	N/A
19	Closing date for receipt of acceptances or renunciations	N/A
20	Names of any underwriters	N/A
21	Amount of any underwriting fee or commission	N/A
22	Names of any brokers to the issue	N/A
23	Fee or commission payable to the broker to the issue	N/A
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders	N/A

25	If the issue is contingent on security holders' approval, the date of the meeting	N/A
26	Date entitlement and acceptance form and prospectus or Product Disclosure Statement will be sent to persons entitled	N/A
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	N/A
28	Date rights trading will begin (if applicable)	N/A
29	Date rights trading will end (if applicable)	N/A
30	How do security holders sell their entitlements <i>in full</i> through a broker?	N/A
31	How do security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	N/A
32	How do security holders dispose of their entitlements (except by sale through a broker)?	N/A
33	Despatch date	13 MARCH 2019


You need only complete this section if you are applying for quotation of securities

(a) ☒ Securities described in Part 1

(b)  All other securities

Entities that have ticked box 34(a)

Tick to indicate you are providing the information or documents

36  If the securities are equity securities, a distribution schedule of the additional securities setting out the number of holders in the categories

- 1 - 1,000
- 1,001 - 5,000
- 5,001 - 10,000
- 10,001 - 100,000
- 100,001 and over

37 ☐ A copy of any trust deed for the additional securities

Entities that have ticked box 34(b)

--

Case No.	Case Name	Case Type	Case Status	Case Date	Case Time	Case Location	Case Description	Case Notes	Case Comments
1	John Doe	Medical	Open	2023-01-01	10:00	Room 101	John Doe, 45 years old, male, presented with chest pain and shortness of breath. Vital signs: BP 120/80, HR 90, RR 20, SpO2 98% on room air. Physical exam: clear lungs, no crackles, no wheezes. ECG: normal sinus rhythm. CXR: clear lungs. Lab: troponin negative, BNP 100. Patient was given aspirin and nitroglycerin. Discharged on home medications. Follow-up in 2 weeks.	Discharged on home medications. Follow-up in 2 weeks.	
2	Jane Smith	Medical	Open	2023-01-02	11:30	Room 102	Jane Smith, 60 years old, female, presented with abdominal pain and nausea. Vital signs: BP 110/70, HR 80, RR 18, SpO2 98% on room air. Physical exam: mild abdominal tenderness, no rebound, no guarding. Lab: WBC 12,000, Hb 12, Plt 250. Patient was given pain medication and anti-nausea medication. Discharged on home medications. Follow-up in 1 week.	Discharged on home medications. Follow-up in 1 week.	
3	Michael Brown	Medical	Open	2023-01-03	14:00	Room 103	Michael Brown, 30 years old, male, presented with fever and cough. Vital signs: BP 100/60, HR 100, RR 22, SpO2 95% on room air. Physical exam: clear lungs, no crackles, no wheezes. Lab: WBC 15,000, Hb 13, Plt 200. Patient was given antibiotics and fever reducers. Discharged on home medications. Follow-up in 1 week.	Discharged on home medications. Follow-up in 1 week.	
4	Sarah Johnson	Medical	Open	2023-01-04	16:00	Room 104	Sarah Johnson, 55 years old, female, presented with dizziness and lightheadedness. Vital signs: BP 90/60, HR 70, RR 16, SpO2 98% on room air. Physical exam: clear lungs, no crackles, no wheezes. Lab: WBC 10,000, Hb 11, Plt 180. Patient was given fluids and anti-nausea medication. Discharged on home medications. Follow-up in 1 week.	Discharged on home medications. Follow-up in 1 week.	
5	David Wilson	Medical	Open	2023-01-05	18:00	Room 105	David Wilson, 70 years old, male, presented with confusion and memory loss. Vital signs: BP 130/90, HR 80, RR 18, SpO2 98% on room air. Physical exam: clear lungs, no crackles, no wheezes. Lab: WBC 11,000, Hb 12, Plt 220. Patient was given fluids and cognitive testing. Discharged on home medications. Follow-up in 1 week.	Discharged on home medications. Follow-up in 1 week.	
6	Emily Davis	Medical	Open	2023-01-06	19:00	Room 106	Emily Davis, 25 years old, female, presented with headache and neck pain. Vital signs: BP 110/70, HR 90, RR 18, SpO2 98% on room air. Physical exam: clear lungs, no crackles, no wheezes. Lab: WBC 10,000, Hb 13, Plt 200. Patient was given pain medication and anti-nausea medication. Discharged on home medications. Follow-up in 1 week.	Discharged on home medications. Follow-up in 1 week.	
7	Robert Miller	Medical	Open	2023-01-07	20:00	Room 107	Robert Miller, 65 years old, male, presented with chest pain and shortness of breath. Vital signs: BP 120/80, HR 90, RR 20, SpO2 98% on room air. Physical exam: clear lungs, no crackles, no wheezes. ECG: normal sinus rhythm. CXR: clear lungs. Lab: troponin negative, BNP 100. Patient was given aspirin and nitroglycerin. Discharged on home medications. Follow-up in 2 weeks.	Discharged on home medications. Follow-up in 2 weeks.	
8	Lisa Anderson	Medical	Open	2023-01-08	21:00	Room 108	Lisa Anderson, 40 years old, female, presented with abdominal pain and nausea. Vital signs: BP 110/70, HR 80, RR 18, SpO2 98% on room air. Physical exam: mild abdominal tenderness, no rebound, no guarding. Lab: WBC 12,000, Hb 12, Plt 250. Patient was given pain medication and anti-nausea medication. Discharged on home medications. Follow-up in 1 week.	Discharged on home medications. Follow-up in 1 week.	
9	James Taylor	Medical	Open	2023-01-09	22:00	Room 109	James Taylor, 35 years old, male, presented with fever and cough. Vital signs: BP 100/60, HR 100, RR 22, SpO2 95% on room air. Physical exam: clear lungs, no crackles, no wheezes. Lab: WBC 15,000, Hb 13, Plt 200. Patient was given antibiotics and fever reducers. Discharged on home medications. Follow-up in 1 week.	Discharged on home medications. Follow-up in 1 week.	
10	Maria Garcia	Medical	Open	2023-01-10	23:00	Room 110	Maria Garcia, 50 years old, female, presented with dizziness and lightheadedness. Vital signs: BP 90/60, HR 70, RR 16, SpO2 98% on room air. Physical exam: clear lungs, no crackles, no wheezes. Lab: WBC 10,000, Hb 11, Plt 180. Patient was given fluids and anti-nausea medication. Discharged on home medications. Follow-up in 1 week.	Discharged on home medications. Follow-up in 1 week.	

- the date from which they do
- the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
- the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

[illegible]

(if issued upon conversion of another security, clearly identify that other security)

Number	Class

Quotation agreement

1 Quotation of our additional securities is in NSX's absolute discretion. NSX may quote the securities on any conditions it decides.

2 We warrant the following to NSX.

- The issue of the securities to be quoted complies with the law and is not for an illegal purpose.
- There is no reason why those securities should not be granted quotation.
- An offer of the securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any securities to be quoted and that no-one has any right to return any securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the securities be quoted.
- We warrant that if confirmation is required under section 1017F of the Corporations Act in relation to the securities to be quoted, it has been provided at the time that we request that the securities be quoted.
- If we are a trust, we warrant that no person has the right to return the securities to be quoted under section 1019B of the Corporations Act at the time that we request that the securities be quoted.

3 We will indemnify NSX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.

4 We give NSX the information and documents required by this form. If any information or document not available now, will give it to NSX before quotation of the securities begins. We acknowledge that NSX is relying on the information and documents. We warrant that they are (will be) true and complete.

G. Acton

Sign here:
(Director/Company secretary)

Date: 13 MARCH 2019

Print name: GEOFF ACTON